{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SD+Vaccine&page=2",
    "query": {
      "intervention": "SD Vaccine",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SD+Vaccine&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-29T23:03:27.892Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04544267",
      "title": "Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Quadrivalent influenza vaccine, high-dose",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent influenza vaccine, standard dose",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "35 Months",
        "sex": "ALL",
        "summary": "6 Months to 35 Months"
      },
      "enrollment_count": 100,
      "start_date": "2020-09-15",
      "completion_date": "2021-06-02",
      "has_results": true,
      "last_update_posted_date": "2025-12-24",
      "last_synced_at": "2026-09-29T23:03:27.892Z",
      "location_count": 10,
      "location_summary": "San Diego, California • Miami, Florida • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "El Dorado",
          "state": "Kansas"
        },
        {
          "city": "Bardstown",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04544267"
    },
    {
      "nct_id": "NCT06361875",
      "title": "A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Quadrivalent Influenza mRNA Vaccine MRT5421",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza mRNA Vaccine MRT5424",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza mRNA Vaccine MRT5429",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza Standard Dose Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza High-Dose Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Recombinant Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 908,
      "start_date": "2024-04-01",
      "completion_date": "2025-06-09",
      "has_results": true,
      "last_update_posted_date": "2026-08-04",
      "last_synced_at": "2026-09-29T23:03:27.892Z",
      "location_count": 11,
      "location_summary": "San Diego, California • Hialeah, Florida • Hollywood, Florida + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06361875"
    },
    {
      "nct_id": "NCT01720277",
      "title": "High Dose Influenza Vaccine in Nursing Home - Pilot Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "HD Fluzone Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SD Fluzone Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Insight Therapeutics, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 2957,
      "start_date": "2012-09",
      "completion_date": "2016-05",
      "has_results": true,
      "last_update_posted_date": "2018-05-23",
      "last_synced_at": "2026-09-29T23:03:27.892Z",
      "location_count": 2,
      "location_summary": "Providence, Rhode Island • Norfolk, Virginia",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01720277"
    },
    {
      "nct_id": "NCT07192458",
      "title": "High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunization; Infection|Transplantation Infection|Influenza",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Fluzone High Dose Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone Standard Dose Inactivated Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2025-09-17",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-07",
      "last_synced_at": "2026-09-29T23:03:27.892Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07192458"
    },
    {
      "nct_id": "NCT01815268",
      "title": "High-Dose Influenza Vaccine in Nursing Homes",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "HD Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SD Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Free Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Usual Care",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Insight Therapeutics, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 823,
      "start_date": "2013-02",
      "completion_date": "2018-09",
      "has_results": false,
      "last_update_posted_date": "2018-07-16",
      "last_synced_at": "2026-09-29T23:03:27.892Z",
      "location_count": 3,
      "location_summary": "Cleveland, Ohio • Providence, Rhode Island • Norfolk, Virginia",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01815268"
    },
    {
      "nct_id": "NCT01867086",
      "title": "Salvage Ovarian FANG™ Vaccine + Carboplatinum",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Stage III Ovarian Cancer",
        "Stage IV Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Vigil™ Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Carboplatinum",
          "type": "DRUG"
        },
        {
          "name": "Carboplatinum and Taxol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Gradalis, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2013-06",
      "completion_date": "2016-04-08",
      "has_results": true,
      "last_update_posted_date": "2018-06-19",
      "last_synced_at": "2026-09-29T23:03:27.892Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01867086"
    },
    {
      "nct_id": "NCT03698279",
      "title": "Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 Months to 17 Years of Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 30 μg (split-virion, inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 45 μg, (split-virion, inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "High-Dose Quadrivalent Influenza Vaccine (QIV-HD) 60 µg (split-virion, inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluarix Quadrivalent Influenza vaccine (Unadjuvanted QIV-SD) (Inactivated)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "FLUAD Pediatric (adjuvanted TIV) (Surface Antigen, Inactivated)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Months to 17 Years"
      },
      "enrollment_count": 665,
      "start_date": "2018-10-09",
      "completion_date": "2019-10-16",
      "has_results": true,
      "last_update_posted_date": "2022-04-04",
      "last_synced_at": "2026-09-29T23:03:27.892Z",
      "location_count": 13,
      "location_summary": "San Diego, California • Miami, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "El Dorado",
          "state": "Kansas"
        },
        {
          "city": "Newton",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03698279"
    },
    {
      "nct_id": "NCT05091307",
      "title": "A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "COVID-19 Prevention"
      ],
      "interventions": [
        {
          "name": "Ad26.COV2.S",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Influenza Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Janssen Vaccines & Prevention B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 861,
      "start_date": "2021-11-02",
      "completion_date": "2022-11-15",
      "has_results": true,
      "last_update_posted_date": "2025-05-25",
      "last_synced_at": "2026-09-29T23:03:27.892Z",
      "location_count": 17,
      "location_summary": "Tempe, Arizona • San Diego, California • Coral Gables, Florida + 12 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05091307"
    },
    {
      "nct_id": "NCT02297542",
      "title": "Immune Response to High-Dose vs. Standard Dose Influenza Vaccine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Elderly Immune System"
      ],
      "interventions": [
        {
          "name": "Flu Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Health Sciences North Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "20 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2014-10",
      "completion_date": "2019-12",
      "has_results": false,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-09-29T23:03:27.892Z",
      "location_count": 1,
      "location_summary": "Farmington, Connecticut",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02297542"
    },
    {
      "nct_id": "NCT01205581",
      "title": "Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV",
        "Cancer"
      ],
      "interventions": [
        {
          "name": "Fluzone High Dose Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Fluzone Standard Dose Vaccine",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 85,
      "start_date": "2010-09",
      "completion_date": "2013-08",
      "has_results": true,
      "last_update_posted_date": "2016-09-23",
      "last_synced_at": "2026-09-29T23:03:27.892Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01205581"
    }
  ]
}